4 interventions in Emerging Therapy graded Early / preclinical.
Hyperbaric Oxygen Therapy (HBOT)
A widely marketed 'age-reversal' therapy built on one small uncontrolled study of surrogate markers from a group that runs commercial clinics. The telomere findings are interesting but unreplicated and unlinked to any health outcome. Be skeptical of clinics charging tens of thousands citing this single paper as proof of rejuvenation.
Mitochondrial Transfer / Transplantation
Real, careful science exists for a narrow ischemia indication, but 'mitochondrial transplant to reverse aging' is essentially theoretical, with no human aging data and unsolved problems of delivery, persistence, and immunogenicity. Any consumer 'mitochondrial therapy' for aging is far ahead of the evidence.
Partial Reprogramming (Yamanaka Factors)
Scientifically the most exciting frontier in rejuvenation, and it has just crossed into humans: the FDA cleared the first OSK gene therapy in January 2026. But that trial is for an eye disease and has no results, mouse lifespan data is the only efficacy evidence, and the cancer risk is real. 'Proven to reverse human aging' is false; 'the frontier just opened its first human trial' is the honest read. Any clinic selling 'reprogramming' rejuvenation today is selling something unproven and potentially dangerous.
Thymus Regeneration (TRIIM)
A genuinely intriguing first human hint that epigenetic age might be reversible and the thymus regrown, widely publicized. But it is 9 people, no control group, and the reversal may reflect growth hormone/metformin rather than thymic rejuvenation. Growth hormone carries real risks. Await the controlled trial before believing the headline.